(a) An overview of the activities of the Pharmacy and Therapeutics Committee and the prospective and retrospective programs;
(b) A summary of interventions made, including the number of cases brought before the committee and the number of interventions made;
(c) An assessment of the impact of the interventions, criteria and standards used, including an overall assessment of the impact of the educational programs and interventions on prescribing and dispensing patterns;
(d) An assessment of the impact of the criteria, standards and educational interventions on quality of care; and
(e) An estimate of the cost savings generated as a result of the prospective and retrospective programs, including an overview of the fiscal impact of the programs to other areas of the medical assistance program such as hospitalization or long term care costs. This analysis should include a cost-benefit analysis of both the prospective and retrospective programs and should take into account the administrative costs of the drug utilization review program.
(2) Copies of the annual report shall be submitted to the President of the Senate, the Speaker of the House of Representatives and other persons who request copies of the report. [2011 c.720 §12]
Note: See note under 414.351.